Kohei shitara (@KoheiShitara) / X

Jeroen Dekervel (@JDekervel) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei shitara (@KoheiShitara) / X

Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert

Kohei Shitara, Videos & Research

Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert

Alexandre Jácome (@AJacomeMD) / X

Raghav Sundar (@sundar__raghav) / X

OncologyTube - DESTINY-Gastric01 Phase II Study Kohei

Raghav Sundar (@sundar__raghav) / X

Kohei shitara (@KoheiShitara) / X

Kohei shitara (@KoheiShitara) / X

Oncology Data Advisor - Zolbetuximab: Gastric/Gastroesophageal Junction Adenocarcinoma

Joseph J Zhao (@josephjzhao) / X

Daniel Catenacci (@DocCatenacci) / X